Zusammenfassung
Diffus-großzellige B-Zell Lymphome (DLBCL) stellen mit
ca. 40 % die größte Gruppe aller
Lymphome dar. Durch die Entwicklung dosisdichter Chemotherapieregime
sowie die Einführung des monoklonalen CD20-Antikörpers
Rituximab hat sich die Prognose fast aller Patienten mit diffus-großzelligen
B-Zell Lymphomen deutlich verbessert. Klinische Risikofaktoren (Alter,
Stadium, LDH, Allgemeinzustand nach ECOG performance status, Ausmaß des
extranodalen Befalls), die bei Diagnosestellung evaluiert werden,
stellen bislang die wirksamste Möglichkeit einer Risikostratifizierung
dar. Eine kombinierte Chemo-Immuntherapie mit R-CHOP ist der Therapiestandard,
der anhand vorliegender Risikofaktoren modifiziert wird.
Summary
Diffuse large B-cell lymphoma represent 40 % of
all lymphoma. The development of dose-dense chemotherapeutic regimens
and the application of the monoclonal CD20 antibody rituximab improve
the prognosis significantly. Evaluation of clinical risk factors
(age, stage, LDH, ECOG performance status, number of extranodal
involvement) at initial diagnosis are the most important approaches
for risk stratification that allows risk adapted modifications of
the standard R-CHOP regimen.
Schlüsselwörter
diffus-großzellige Lymphome - Risikofaktoren - Chemo-Immuntherapie - R-CHOP
Key words
diffuse large cell lymphoma - risk factors - chemoimmunotherapy - R-CHOP
Literatur
-
1
Coiffier B, Lepage E, Briere J. et al .
CHOP chemotherapy plus rituximab compared
with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
N Engl J Med.
2002;
346
235-42
-
2
Dunleavy K, Pittaluga S, Janik J. et al .
Primary mediastinal large B-cell lymphoma
(PMBL) outcome is significantly improved by the addition of rituximab
to dose adjusted (DA)-EPOCH and overcomes the need for radiation.
Blood.
2005;
106
273A
-
3
Fisher R I, Gaynoer E R, Dahlberg S. et al .
Comparison of a standard regimen (CHOP)
with three intensive chemotherapy regimens for advanced non-Hodgkin’s
lymphoma.
N Eng J Med.
1993;
328
1002-6
-
4
Glass B, Kloess M, Reiser M. et
al .
Dose-escalated CHOP + Etoposide followed
by repetitive autologous stem cell transplantation (MegaCHOEP) with
or without rituximab for primary treatment of aggressive NHL.
Blood.
2006;
106
1492a
-
5 Gleissner B, Küppers R, Siebert R. et al .Report of a workshop on malignant lymphoma:
a review of molecular and clinical risk profiling. Brit
J Haemtol in press
-
6
Haioun C, Itti E, Rahmoundi A. et al .
[18F] fluoro-2-deoxy-D-glucose
positron emission tomography (FDG-PET) in aggressive lymphoma: an
early prognostic tool for predicting patient outcome.
Blood.
2005;
106
(4)
1376-81
, . Epub 2005 Apr 28
-
7
Harris N L, Jaffe E S, Diebold J. et al .
The World Health Organization classification
of hematological malignancies report of the Clinical Advisory Committee
Meeting, Airlie House, Virginia, November 1997.
Mod Pathol.
2000;
13
193-207
-
8 Hoelzer D, Hiddemann W, Baumann A. et al .High cure rate of adult Burkitt’s
and other high grade NHL by the combination of short intensive chemotherapy
cycles with rituximab. Annual Meeting European Organization
of Haematology EHA 2007: 0410a
-
9 http://www.krebsregister.saarland.de/publikationen/PDF/Publikation40Jahre.pdf.
-
10
Hummel M, Bentink S, Berger H. et al .
A biologic definition of Burkitt’s
lymphoma from transcriptional and genomic profiling.
New
England Journal of Medicine.
2006;
354
2419-2430
-
11
Küppers R.
Mechanisms of B-cell pathogenesis.
Nat Rev Cancer.
2005;
5
(4)
251-262
-
12
Miller T P, LeBlanc M, Spier C. et al .
CHOP alone compared to CHOP plus radiotherapy
for early stage aggressive non-Hodgkin’s lymphomas: Update
of the Southwest Oncology Group randomized trial.
Blood.
2001;
98
724a
-
13
Pfreundschuh M, Trümper L, Kloess M. et al .
Two-weekly or 3-weekly CHOP chemotherapy
with or without etoposide for the treatment of young patients with
good-prognosis (normal LDH) aggressive lymphomas: results of the
NHL-B1 trial of the DSNHL.
Blood.
2004;
104
626-33
-
14
Pfreundschuh M, Schubert J, Ziepert M. et al .
Six versus eight cycles of bi-weekly CHOP-14
with or without rituximab in elderly patients with aggressive CD20+ B-cell
lymphomas: a randomised controlled trial (RICOVER-60).
Lancet
Oncol.
2008;
9
105-116
-
15
Pfreundschuh M, Trumper L, Osterborg A. et al .
CHOP-like chemotherapy plus rituximab versus
CHOP-like chemotherapy alone in young patients with good-prognosis
diffuse large-B-cell lymphoma: a randomised controlled trial by
the MabThera International Trial (MInT) Group.
Lancet
Oncol.
2006;
7
379-391
-
16
Reyes F, Lepage E, Ganem G. et al .
ACVBP versus CHOP plus radiotherapy for
localized aggressive lymphoma.
N Eng J Med.
2005;
352
1197-205
-
17
Schmitz N, Kloess M, Reiser M. et al .
Four versus six courses of a dose-escalated
cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)
regimen plus etoposide (MegaCHOEP) and autologous stem cell transplantation.
Cancer.
2006;
106
136-45
-
18
Seam P, Juweid M F, Cheson B D.
The role of FDG-PET scans in patients with
lymphoma.
Blood.
2007;
110
(10)
3507-16
, . Epub 2007 Aug 2
-
19
Shipp M A.
Prognostic factors in aggressive non-Hodgkin’s lymphoma:
who has „high-risk” disease?.
Blood.
1994;
83
1165-1173
-
20
Tilly H, Lipage E, Coiffier B. et al .
Intensive conventional chemotherapy (ACVBP
regimen) compared with standard CHOP for poor-prognosis aggressive
non-Hodgkin lymphoma.
Blood.
2003;
102
4284-4289
-
21
Zinzani P L, Martelli M, Bertini M. et al .
Induction chemotherapy strategies for primary
mediastinal large B-cell lymphoma with sclerosis: a retrospective
multinational study on 426 previously untreated patients.
Haemagologica.
2002;
87
1258-64
Dr. med. B. Gleissner
Klinik für Innere Medizin I
Kirrberger
Straße
66424 Homburg/Saar
Phone: 06841/1623083
Fax: 06841/1621399
Email: beate.gleissner@uniklinikum-saarland.de
